Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

AbbVie (ABBV) Stock Price & Analysis

ABBV Stock Chart & Stats

MX$5,545.00MX$85.00(1.56%)
At close:
MXN 4,500MXN 5,000MXN 5,5003 Aug18 Aug31 Aug15 Sep28 Sep12 Oct28 Oct
Day’s Range
MXN 5,544.00 - MXN 5,582.00
52-Week Range
MXN 3,350.11 - MXN 5,582.00
Previous Close
MXN 5,460.00
Volume
31
Average Volume (3M)
259
Market Cap
MXN 9.79T
Enterprise Value
MXN 509.95B
Total Cash (Recent Filing)
MXN 6.57B
Total Debt (Recent Filing)
MXN 70.82B
Price to Earnings (P/E)
83.1
Beta
-0.25
Next Earnings
Feb 03, 2027 (Est.)
EPS Estimate
73.49
Next Dividend Ex-Date
N/A
Dividend Yield
2.31%

Bulls Say, Bears Say

Bulls Say

Growth Franchises

Rapid growth in Skyrizi and Rinvoq is strengthening AbbVie’s post-Humira portfolio and reducing dependence on a single legacy product. Their scale, differentiated clinical profiles, and expanding indications support durable revenue growth and help sustain the company’s strong operating profitability.

Pipeline Expansion

The Apogee acquisition broadens AbbVie’s immunology pipeline across several large chronic disease categories and adds potential follow-on products beyond current franchises. Although development and integration take time, the assets improve long-term product depth and support future competitive positioning.

Cash Generation

Very strong operating and free cash flow demonstrates that AbbVie converts reported earnings into substantial cash, providing capacity to fund research, dividends, acquisitions, and debt reduction. This cash-generation base supports strategic flexibility even while the company manages a leveraged capital structure.

Bears Say

High Leverage

High debt combined with negative equity makes AbbVie’s capital structure less resilient and reduces flexibility if operating results weaken. Annual operating cash flow covers only a moderate portion of total debt, so meaningful deleveraging depends on sustained cash generation over multiple years.

Legacy Franchise Erosion

Biosimilar competition and policy-driven pricing pressure are reducing revenue from important legacy franchises. Continued erosion can offset newer-product growth, weaken portfolio mix, and make future performance increasingly dependent on successful launches, indication expansion, and sustained execution in replacement franchises.

Aesthetics Weakness

Weakness in Aesthetics, particularly the Juvéderm filler franchise, shows that this business is facing more than isolated product volatility. Continued category pressure and lower consumer confidence could weigh on portfolio diversification and leave AbbVie more reliant on immunology and neuroscience growth.

AbbVie News

ABBV FAQ

What was AbbVie’s price range in the past 12 months?
AbbVie lowest stock price was Mex$3350.11 and its highest was Mex$5582.00 in the past 12 months.
What is AbbVie’s market cap?
AbbVie’s market cap is Mex$9.79T.
When is AbbVie’s upcoming earnings report date?
AbbVie’s next earnings report is estimated for Feb 03, 2027 (not yet confirmed), which is in 94 days.
How were AbbVie’s earnings last quarter?
AbbVie released its earnings results on Oct 30, 2026. The company reported Mex$71.765 earnings per share for the quarter, beating the consensus estimate of Mex$69.999 by Mex$1.766.
Is AbbVie overvalued?
According to Wall Street analysts AbbVie’s price is currently Overvalued.
Does AbbVie pay dividends?
AbbVie does not currently pay dividends.
What is AbbVie’s EPS estimate?
AbbVie’s EPS estimate is 73.49.
How many shares outstanding does AbbVie have?
AbbVie has 1,767,117,300 shares outstanding.
What happened to AbbVie’s price movement after its last earnings report?
AbbVie reported an EPS of Mex$71.765 in its last earnings report, beating expectations of Mex$69.999. Following the earnings report the stock price went up 1.557%.
Which hedge fund is a major shareholder of AbbVie?
Hedge funds hold AbbVie shares: hedge funds increased their holdings by 1.1M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology